Ecdysone analog that acts as an inducer of ecdysone-inducible gene expression systems in mammalian cells and transgenic animals. Stimulates Bcl-XL mRNA transcription and inhibits TRAIL- and hFasL-induced apoptosis in RKO cells.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solubility||Soluble in DMSO|
Preparing Stock Solutions
The following data is based on the product molecular weight 496.63. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||2.01 mL||10.07 mL||20.14 mL|
|5 mM||0.4 mL||2.01 mL||4.03 mL|
|10 mM||0.2 mL||1.01 mL||2.01 mL|
|50 mM||0.04 mL||0.2 mL||0.4 mL|
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.
References are publications that support the products' biological activity.
Patrick et al (2001) Muristerone A-induced nerve growth factor release from genetically engineered human dermal fibroblasts for peripheral nerve tissue engineering. Tissue Eng. 7 303 PMID: 11429150
Bosser and Zornig (2005) Agonists of an ecdysone-inducible mammalian expression system inhibit Fas-ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO. Cell Death Diff. 13 189 PMID:
If you know of a relevant reference for Muristerone A, please let us know.
Keywords: ecdysone analogs analogues inhibits antiapoptotic Bcl-XL inducing agents MuristeroneA Bcl-2 Family
Citations for Muristerone A
Citations are publications that use Tocris products.
Currently there are no citations for Muristerone A. Do you know of a great paper that uses Muristerone A from Tocris? If so please let us know.
Literature in this Area
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Programmed Cell Death Poster
There are two currently recognized forms of programmed cell death: apoptosis and necroptosis. This poster summarizes the signaling pathways involved in apoptosis, necroptosis and cell survival following death receptor activation, and highlights the influence of the molecular switch, cFLIP, on cell fate.